📊 EHC Key Takeaways
Is Encompass Health Corp (EHC) a Good Investment?
Encompass Health demonstrates solid profitability with strong margins (16.1% operating, 9.5% net) and exceptional returns on equity (23.2%), supported by 10.5% revenue growth and impressive 27.1x interest coverage. However, significant concerns exist around negative free cash flow (-$301.8M, -5.1% FCF margin) despite positive operating cash flow, indicating capital intensity exceeds cash generation, coupled with weak liquidity (1.08x current ratio) and elevated leverage (1.00x debt-to-equity with $2.4B long-term debt).
Encompass Health shows solid core fundamentals, with double-digit revenue growth, strong operating profitability, and excellent interest coverage that indicates debt is currently manageable. The main offset is weak cash conversion, with negative free cash flow driven by heavy capital spending and a very small cash cushion, so the case depends on whether recent investment translates into sustained earnings and cash flow growth.
Why Buy Encompass Health Corp Stock? EHC Key Strengths
- Strong operating margin of 16.1% with net margin of 9.5% demonstrates effective cost management and operational efficiency
- Exceptional return on equity of 23.2% and ROA of 8.0% indicate efficient capital deployment and strong profitability relative to shareholder investment
- Robust revenue growth of 10.5% YoY with EPS growth of 24.2% showing earnings leverage and operational scaling
- Excellent interest coverage ratio of 27.1x provides substantial debt servicing capacity and financial stability
- Revenue grew 10.5% year over year while operating margin remained strong at 16.1%, indicating healthy operating leverage
- ROE of 23.2% and ROA of 8.0% point to efficient use of capital and solid profitability for a hospital operator
- Interest coverage of 27.1x suggests the company can comfortably service its debt under current earnings levels
EHC Stock Risks: Encompass Health Corp Investment Risks
- Significant negative free cash flow of -$301.8M despite $434.6M operating cash flow indicates capital expenditures of $736.4M exceed operating cash generation, raising sustainability concerns
- Weak liquidity position with current ratio of only 1.08x and minimal cash reserves of $72.2M relative to $2.4B long-term debt creates vulnerability to operational disruptions
- Capital intensity appears structurally challenged with CapEx consuming 12.5% of revenue annually, limiting financial flexibility and dividend/buyback capacity
- High leverage at 1.00x debt-to-equity ratio combined with low cash position elevates refinancing risk and limits strategic flexibility
- Free cash flow was negative at -$301.8M, which weakens the quality of earnings and raises dependence on future cash generation
- Cash is low at $72.2M relative to $2.45B of long-term debt, leaving limited balance sheet flexibility
- Net income growth was only 0.3% despite much stronger revenue growth, which may indicate margin pressure below the operating line or higher financing and other costs
Key Metrics to Watch
- Free cash flow trend and CapEx sustainability relative to operating cash flow generation
- Liquidity improvement through cash balance growth and current ratio expansion
- Debt reduction pace and leverage ratio movement toward healthier levels below 0.75x
- Operating margin maintenance amid potential labor cost inflation in healthcare services
- Capital expenditure efficiency and ROI on facility investments
- Free cash flow and capital expenditure intensity
- Net income margin and cash balance relative to debt
Encompass Health Corp (EHC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Encompass Health Corp presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
EHC Profit Margin, ROE & Profitability Analysis
EHC vs Healthcare Sector: How Encompass Health Corp Compares
How Encompass Health Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Encompass Health Corp Stock Overvalued? EHC Valuation Analysis 2026
Based on fundamental analysis, Encompass Health Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Encompass Health Corp Balance Sheet: EHC Debt, Cash & Liquidity
EHC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Encompass Health Corp's revenue has grown significantly by 16% over the 5-year period, indicating strong business expansion. The most recent EPS of $3.47 reflects profitable operations.
EHC Revenue Growth, EPS Growth & YoY Performance
EHC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.4B | $108.2M | $1.06 |
| Q2 2025 | $1.3B | $114.1M | $1.12 |
| Q1 2025 | $1.3B | $112.5M | $1.10 |
| Q3 2024 | $1.2B | $85.3M | $0.84 |
| Q2 2024 | $1.2B | $91.4M | $0.90 |
| Q1 2024 | $1.2B | $87.7M | $0.87 |
| Q3 2023 | $1.1B | $45.4M | $0.45 |
| Q2 2023 | $1.1B | $48.7M | $0.49 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Encompass Health Corp Dividends, Buybacks & Capital Allocation
EHC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Encompass Health Corp (CIK: 0000785161)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EHC
What is the AI rating for EHC?
Encompass Health Corp (EHC) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EHC's key strengths?
Claude: Strong operating margin of 16.1% with net margin of 9.5% demonstrates effective cost management and operational efficiency. Exceptional return on equity of 23.2% and ROA of 8.0% indicate efficient capital deployment and strong profitability relative to shareholder investment. ChatGPT: Revenue grew 10.5% year over year while operating margin remained strong at 16.1%, indicating healthy operating leverage. ROE of 23.2% and ROA of 8.0% point to efficient use of capital and solid profitability for a hospital operator.
What are the risks of investing in EHC?
Claude: Significant negative free cash flow of -$301.8M despite $434.6M operating cash flow indicates capital expenditures of $736.4M exceed operating cash generation, raising sustainability concerns. Weak liquidity position with current ratio of only 1.08x and minimal cash reserves of $72.2M relative to $2.4B long-term debt creates vulnerability to operational disruptions. ChatGPT: Free cash flow was negative at -$301.8M, which weakens the quality of earnings and raises dependence on future cash generation. Cash is low at $72.2M relative to $2.45B of long-term debt, leaving limited balance sheet flexibility.
What is EHC's revenue and growth?
Encompass Health Corp reported revenue of $5.9B.
Does EHC pay dividends?
Encompass Health Corp pays dividends, with $71.1M distributed to shareholders in the trailing twelve months.
Where can I find EHC SEC filings?
Official SEC filings for Encompass Health Corp (CIK: 0000785161) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EHC's EPS?
Encompass Health Corp has a diluted EPS of $5.54.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EHC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Encompass Health Corp has a BUY rating with 70% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is EHC stock overvalued or undervalued?
Valuation metrics for EHC: ROE of 23.2% (sector avg: 15%), net margin of 9.5% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy EHC stock in 2026?
Our dual AI analysis gives Encompass Health Corp a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EHC's free cash flow?
Encompass Health Corp's operating cash flow is $434.6M, with capital expenditures of $736.4M. FCF margin is -5.1%.
How does EHC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 9.5% (avg: 12%), ROE 23.2% (avg: 15%), current ratio 1.08 (avg: 2).